Aardvark Therapeutics Statistics
Total Valuation
AARD has a market cap or net worth of $106.46 million. The enterprise value is $13.64 million.
Important Dates
The next estimated earnings date is Wednesday, August 12, 2026, after market close.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AARD has 21.82 million shares outstanding. The number of shares has increased by 245.54% in one year.
| Current Share Class | 21.82M |
| Shares Outstanding | 21.82M |
| Shares Change (YoY) | +245.54% |
| Shares Change (QoQ) | +0.15% |
| Owned by Insiders (%) | 16.33% |
| Owned by Institutions (%) | 23.20% |
| Float | 10.91M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.20 |
| P/TBV Ratio | 1.20 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.06, with a Debt / Equity ratio of 0.00.
| Current Ratio | 8.06 |
| Quick Ratio | 7.86 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -58.79% and return on invested capital (ROIC) is -39.12%.
| Return on Equity (ROE) | -58.79% |
| Return on Assets (ROA) | -36.54% |
| Return on Invested Capital (ROIC) | -39.12% |
| Return on Capital Employed (ROCE) | -85.90% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.75M |
| Employee Count | 40 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -63.67% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -63.67% |
| 50-Day Moving Average | 4.73 |
| 200-Day Moving Average | 9.36 |
| Relative Strength Index (RSI) | 59.61 |
| Average Volume (20 Days) | 212,265 |
Short Selling Information
The latest short interest is 911,832, so 4.18% of the outstanding shares have been sold short.
| Short Interest | 911,832 |
| Short Previous Month | 987,661 |
| Short % of Shares Out | 4.18% |
| Short % of Float | 8.36% |
| Short Ratio (days to cover) | 5.01 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -74.72M |
| Pretax Income | -69.87M |
| Net Income | -69.87M |
| EBITDA | -74.68M |
| EBIT | -74.72M |
| Earnings Per Share (EPS) | -$3.21 |
Full Income StatementBalance Sheet
The company has $91.20 million in cash and $336,000 in debt, giving a net cash position of $90.86 million or $4.16 per share.
| Cash & Cash Equivalents | 91.20M |
| Total Debt | 336,000 |
| Net Cash | 90.86M |
| Net Cash Per Share | $4.16 |
| Equity (Book Value) | 86.99M |
| Book Value Per Share | 3.99 |
| Working Capital | 81.98M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$61.65 million and capital expenditures -$95,000, giving a free cash flow of -$61.75 million.
| Operating Cash Flow | -61.65M |
| Capital Expenditures | -95,000 |
| Depreciation & Amortization | 42,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -61.75M |
| FCF Per Share | -$2.83 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |